For debate: that Australia should continue using the quadrivalent vaccine

Sex Health. 2010 Sep;7(3):235-7. doi: 10.1071/sh09129.
No abstract available

Publication types

  • Comparative Study
  • Editorial

MeSH terms

  • Adolescent
  • Adult
  • Australia
  • Child
  • Cost-Benefit Analysis
  • Female
  • Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
  • Humans
  • Mass Screening / economics
  • Mass Vaccination* / economics
  • Papillomavirus Infections / economics
  • Papillomavirus Infections / immunology
  • Papillomavirus Infections / prevention & control*
  • Papillomavirus Vaccines / administration & dosage*
  • Papillomavirus Vaccines / economics
  • Papillomavirus Vaccines / immunology
  • Sexually Transmitted Diseases, Viral / economics
  • Sexually Transmitted Diseases, Viral / immunology
  • Sexually Transmitted Diseases, Viral / prevention & control*
  • Uterine Cervical Neoplasms / economics
  • Uterine Cervical Neoplasms / immunology
  • Uterine Cervical Neoplasms / prevention & control*
  • Vaginal Smears / economics

Substances

  • Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
  • Papillomavirus Vaccines
  • human papillomavirus vaccine, L1 type 16, 18